top of page

Top 5 HEOR Stats Impacting Drug Development


biotech consulting firm in Boston, pharma consulting firm in Boston, life science consulting firm in Boston, biopharma consulting firm in Boston, pharmaceutical consulting firm in Boston, biotechnology consulting firm in Boston

Health Economics and Outcomes Research (HEOR) is a critical component in the pharmaceutical and biotechnology sectors, influencing decisions from drug development to market access. The role of HEOR has grown significantly as the industry faces increasing pressure to demonstrate the value of new therapies. This article delves into the top five HEOR statistics that are currently shaping drug development, offering insights into the complex landscape of healthcare economics.


Only 30% of New Drugs Achieve Market Access without HEOR Support


One of the most striking statistics is that only 30% of new drugs gain market access without robust HEOR support. This highlights the critical role that HEOR plays in providing evidence of a drug’s value, efficacy, and cost-effectiveness. As payers and healthcare systems become more cost-conscious, the need for comprehensive HEOR data to support pricing and reimbursement decisions becomes imperative.


75% of Pharma Companies Utilize HEOR for Strategic Decision-Making

A staggering 75% of pharmaceutical companies now integrate HEOR into their strategic decision-making processes. This integration helps in identifying the most promising drug candidates, optimizing clinical trial designs, and developing effective market access strategies. HEOR provides a framework for understanding the broader impact of new therapies, including their economic and quality-of-life benefits.


65% Increase in HEOR Investment by Biotech Firms in the Last Decade

Over the past decade, biotech firms have increased their investment in HEOR by 65%. This surge reflects the growing recognition of HEOR’s importance in demonstrating the value proposition of innovative therapies, particularly those targeting rare or complex conditions. Increased investment in HEOR enables biotech companies to better navigate the regulatory and reimbursement landscapes, ultimately improving the likelihood of successful product launches.


Less than 20% of New Drug Applications (NDAs) Are Approved Without HEOR Evidence

Less than 20% of New Drug Applications (NDAs) are approved without substantial HEOR evidence. Regulatory bodies and payers increasingly require comprehensive HEOR data to make informed decisions about new therapies. This statistic underscores the necessity for drug developers to incorporate HEOR early in the drug development process to ensure regulatory approval and market access.


85% of Biopharma Consulting Projects Involve HEOR Components

A remarkable 85% of biopharma consulting projects now involve HEOR components. Consulting firms, particularly those based in major biotech hubs like Boston, play a pivotal role in guiding companies through the complexities of HEOR. Firms such as biotech consulting firms in Boston, pharma consulting firms in Boston, and life science consulting firms in Boston are essential in helping companies develop HEOR strategies that enhance the value proposition of their therapies.


The impact of HEOR on drug development is undeniable, as evidenced by the critical statistics outlined in this article. From achieving market access to securing regulatory approval, HEOR is an essential tool for demonstrating the value of new therapies. The expertise provided by consulting firms, particularly those in Boston, is invaluable in navigating this complex landscape. As the demand for HEOR continues to grow, companies that invest in robust HEOR strategies will be better positioned to succeed in the competitive pharmaceutical and biotechnology markets.


Contact BioBoston Consulting today or visit our website to learn more about how we can support your organization.


2 views0 comments

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating

Subscribe to Our Newsletter

Thanks for submitting!

bottom of page